Outcome of Board Meeting.
ABBOTINDIA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Abbott India reported steady growth for Q1 FY26 (quarter ended June 30, 2025). Revenue from operations rose to ₹1,738.35 Cr from ₹1,557.61 Cr in Q1 FY25, up about 11.6%. Profit after tax grew to ₹365.86 Cr from ₹328.01 Cr, a rise of roughly 11.5%. Earnings per share stood at ₹172.17 versus ₹154.36 last year. The company operates only in the Pharmaceuticals segment. Additionally, the Board approved the appointment of Mr. Darshan Gada as an Additional Non-Executive Director effective August 18, 2025, subject to shareholder approval via postal ballot. The statutory auditors Walker Chandiok & Co LLP issued a clean limited review report with no qualifications.
Results are solid and in line with expectations — double-digit growth in both revenue and profit with stable margins. No red flags from the auditor. The new director appointment is routine and unlikely to move the stock; shareholder focus will remain on whether the pharma growth momentum continues.